Tags

Type your tag names separated by a space and hit enter

Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization.
Sci China Life Sci. 2020 May 06 [Online ahead of print]SC

Abstract

This study aimed to explore macrophage polarization in acute graft-versus-host disease after hematopoietic stem cell transplantation, and investigated if arsenic trioxide (ATO) could correct this imbalance. In the colon of GVHD mice, we found that the number of F4/80+iNOS+ cells as well as the expression intensity of TNF-α and IL-1β was greater in the GVHD group than in the BM group, whereas the number of F4/80+CD206+ cells and the expression intensity of IL-10 and TGF-β was greater in the BM group than in the GVHD group. We investigated the effect of ATO on GVHD mice, and found that ATO treatment clearly improved the survival of the mice and reduced the severity of GVHD. In addition, ATO reduced the number of F4/80+iNOS+ cells, and increased the number of F4/80+CD206+ cells in the colon of GVHD mice. Furthermore, ATO sharply decreased CD86 and CD80 expression, and increased CD163 and CD206 expression in macrophages induced from aGVHD patients. Therefore, ATO can modulate the M1 and M2 phenotype in GVHD mice or in macrophages from aGVHD patients. Our data suggest that macrophage polarization is involved in the pathogenesis of aGVHD, and ATO treatment modulates macrophage polarization toward an M2 phenotype.

Authors+Show Affiliations

Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. Peking University Institute of Hematology, Beijing, 100044, China. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.Peking University People's Hospital, Beijing, 100044, China. zhangxh100@sina.com. Peking University Institute of Hematology, Beijing, 100044, China. zhangxh100@sina.com. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China. zhangxh100@sina.com. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China. zhangxh100@sina.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32382983

Citation

Liu, Xiao, et al. "Arsenic Trioxide Alleviates Acute Graft-versus-host Disease By Modulating Macrophage Polarization." Science China. Life Sciences, 2020.
Liu X, Su Y, Sun X, et al. Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. Sci China Life Sci. 2020.
Liu, X., Su, Y., Sun, X., Fu, H., Huang, Q., Chen, Q., Mo, X., Lv, M., Kong, Y., Xu, L., Huang, X., & Zhang, X. (2020). Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. Science China. Life Sciences. https://doi.org/10.1007/s11427-019-1691-x
Liu X, et al. Arsenic Trioxide Alleviates Acute Graft-versus-host Disease By Modulating Macrophage Polarization. Sci China Life Sci. 2020 May 6; PubMed PMID: 32382983.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. AU - Liu,Xiao, AU - Su,Yan, AU - Sun,Xueyan, AU - Fu,Haixia, AU - Huang,Qiusha, AU - Chen,Qi, AU - Mo,Xiaodong, AU - Lv,Meng, AU - Kong,Yuan, AU - Xu,Lanping, AU - Huang,Xiaojun, AU - Zhang,Xiaohui, Y1 - 2020/05/06/ PY - 2019/12/26/received PY - 2020/03/27/accepted PY - 2020/5/9/entrez KW - ATO KW - acute graft-versus-host disease KW - macrophage polarization JF - Science China. Life sciences JO - Sci China Life Sci N2 - This study aimed to explore macrophage polarization in acute graft-versus-host disease after hematopoietic stem cell transplantation, and investigated if arsenic trioxide (ATO) could correct this imbalance. In the colon of GVHD mice, we found that the number of F4/80+iNOS+ cells as well as the expression intensity of TNF-α and IL-1β was greater in the GVHD group than in the BM group, whereas the number of F4/80+CD206+ cells and the expression intensity of IL-10 and TGF-β was greater in the BM group than in the GVHD group. We investigated the effect of ATO on GVHD mice, and found that ATO treatment clearly improved the survival of the mice and reduced the severity of GVHD. In addition, ATO reduced the number of F4/80+iNOS+ cells, and increased the number of F4/80+CD206+ cells in the colon of GVHD mice. Furthermore, ATO sharply decreased CD86 and CD80 expression, and increased CD163 and CD206 expression in macrophages induced from aGVHD patients. Therefore, ATO can modulate the M1 and M2 phenotype in GVHD mice or in macrophages from aGVHD patients. Our data suggest that macrophage polarization is involved in the pathogenesis of aGVHD, and ATO treatment modulates macrophage polarization toward an M2 phenotype. SN - 1869-1889 UR - https://www.unboundmedicine.com/medline/citation/32382983/Arsenic_trioxide_alleviates_acute_graft-versus-host_disease_by_modulating_macrophage_polarization L2 - https://dx.doi.org/10.1007/s11427-019-1691-x DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.